Abstract
This review focuses on the current findings regarding interaction between amyloid β peptide (Aβ) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimers disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Aβ on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Aβ-RAGE interaction exaggerates neuronal stress, accumulation of Aβ, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Aβ-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.
Keywords: amyloid precursor protein, AD brains, neurofibrillary tangles, endothelin 1, blood-brain barrier
Current Molecular Medicine
Title: RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Volume: 7 Issue: 8
Author(s): Shi Du Yan, Xi Chen, Douglas G. Walker, Ann Marie Schmidt, Ottavio Arancio and Lih-Fen Lue
Affiliation:
Keywords: amyloid precursor protein, AD brains, neurofibrillary tangles, endothelin 1, blood-brain barrier
Abstract: This review focuses on the current findings regarding interaction between amyloid β peptide (Aβ) and receptor for advanced glycation endproducts (RAGE) and its roles in the pathogenesis of Alzheimers disease (AD). As a ubiquitously expressed cell surface receptor, RAGE mediates the effects of Aβ on microglia, blood-brain barrier (BBB) and neurons through activating different signaling pathways. Data from autopsy brain tissues, in vitro cell cultures and transgenic mouse models suggest that Aβ-RAGE interaction exaggerates neuronal stress, accumulation of Aβ, impaired learning memory, and neuroinflammation. Blockade of RAGE protects against Aβ-mediated cellular perturbation. These findings may have an important therapeutic implication for neurodegenerative disorders relevant to AD.
Export Options
About this article
Cite this article as:
Yan Du Shi, Chen Xi, Walker G. Douglas, Schmidt Marie Ann, Arancio Ottavio and Lue Lih-Fen, RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease, Current Molecular Medicine 2007; 7 (8) . https://dx.doi.org/10.2174/156652407783220741
DOI https://dx.doi.org/10.2174/156652407783220741 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Introduction from the Editor-In-Chief
Current Neurovascular Research Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Is the Use of Proton-pump Inhibitors a Risk Factor for Alzheimer’s Disease? Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy Gene Therapy, A Novel Therapeutic Tool for Neurological Disorders: Current Progress, Challenges and Future Prospective
Current Gene Therapy 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Anti-Acetylcholinesterase Derivatives: A Privileged Structural Framework in Drug Discovery to Treat Alzheimer’s Disease
Current Enzyme Inhibition Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Synthesis, Antioxidant, Anticancer and Antiviral Activities of Novel Quinoxaline Hydrazone Derivatives and their Acyclic C-Nucleosides
Medicinal Chemistry Proteasomes as Drug Targets
Current Drug Targets Phenolic Compounds from Plants as Nitric Oxide Production Inhibitors
Current Medicinal Chemistry Generation and Transplantation of Dopaminergic Neurons Derived from Embryonic Stem Cells
Current Stem Cell Research & Therapy Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters